Abstracts

Rationale: Purpose of this study is to evaluate efficency and safety of eslicarbazepine acetate (Aptiom) in adult patients with refractory epilepsy on two or more drugs.Methods: Patients were selected from predominately outpatient epilepsy center. Patients were considered for the study if they fit the criteria of being established with one or more of the following: Clinical depression, partial epilepsy, generlized epilepsy or epilepsy with multiple handicaps. So far 12 patients were available for data analysis. 5 were males and 7 were females. Age ranging from 21 years old to 65 years old. 10 of the patients were on Vagal Nerve Device (VNS) implant on maximum tolerable parameters including Output current of 3.5 mA. and Magnet Current of 3.5 mA. Signal Frequency was a maximum of 30 Hz. As well as Magnet Pulse Width at a maximum of 1000 microseconds. Patients were on two or more antiepileptic medications with levels being therapeutic. The dosage of Aptiom ranged from 800 mg to 1200 mg per day. Patients were given medicine between 9 am and Noon.Results: 10 out of 12 patients had 50% or more reduction in seizure frequency. 2 out of 12 could not continue Aptiom for unacceptable side effects. Original seizure frequency ranged from 2 - 3 per day to 7 - 10 per day and varied per patient.Conclusions: Despire the small number of patients at present, it appears esilcarbazepine acetate reflected noticeable improvement in seizure control and better quality of life. More data on additional patients would be available at the time of the AES meeting in Philadelphia 2015. Patient demographics and details of VNS parameters will be available for every patient.